What is the share price of Vimta Labs Ltd (VIMTALABS) today?
The share price of VIMTALABS as on 15th June 2026 is ₹546. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Vimta Labs Ltd (VIMTALABS) share?
The past returns of Vimta Labs Ltd (VIMTALABS) share are- Past 1 week: 0.86%
- Past 1 month: 18.25%
- Past 3 months: 30.50%
- Past 6 months: -10.43%
- Past 1 year: 12.42%
- Past 3 years: 160.33%
- Past 5 years: 316.38%
What are the peers or stocks similar to Vimta Labs Ltd (VIMTALABS)?
The peers or stocks similar to Vimta Labs Ltd (VIMTALABS) include:What is the dividend yield % of Vimta Labs Ltd (VIMTALABS) share?
The current dividend yield of Vimta Labs Ltd (VIMTALABS) is 0.37.What is the market cap of Vimta Labs Ltd (VIMTALABS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vimta Labs Ltd (VIMTALABS) is ₹2438.95 Cr as of 15th June 2026.What is the 52 week high and low of Vimta Labs Ltd (VIMTALABS) share?
The 52-week high of Vimta Labs Ltd (VIMTALABS) is ₹902.65 and the 52-week low is ₹376.05.What is the PE and PB ratio of Vimta Labs Ltd (VIMTALABS) stock?
The P/E (price-to-earnings) ratio of Vimta Labs Ltd (VIMTALABS) is 31.47. The P/B (price-to-book) ratio is 5.34.Which sector does Vimta Labs Ltd (VIMTALABS) belong to?
Vimta Labs Ltd (VIMTALABS) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Vimta Labs Ltd (VIMTALABS) shares?
You can directly buy Vimta Labs Ltd (VIMTALABS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Vimta Labs Ltd
VIMTALABS Share Price
NSE₹546.001.60% (-8.85)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VIMTALABS Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
VIMTALABS Performance & Key Metrics
VIMTALABS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 31.46 | 5.34 | 0.37% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.95 | 6.11 | 0.57% |
VIMTALABS Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VIMTALABS Company Profile
Vimta Labs Limited is engaged in providing testing and contract research services in the fields of clinical and pre-clinical studies, clinical reference, analytical testing, advanced molecular biology and environmental studies.
DIVISLAB
PE Ratio
68.32
68.32
1Y Return
1.18%
1.18%
Buy Reco %
62.50
62.50
SYNGENE
PE Ratio
57.63
57.63
1Y Return
31.32%
31.32%
Buy Reco %
62.50
62.50
AARTIPHARM
PE Ratio
33.25
33.25
1Y Return
26.73%
26.73%
Buy Reco %
0.00
0.00
PE Ratio
29.00
29.00
1Y Return
34.29%
34.29%
Buy Reco %
0.00
0.00
PE Ratio
32.71
32.71
1Y Return
49.57%
49.57%
Buy Reco %
0.00
0.00
VIMTALABS Sentiment Analysis
VIMTALABS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
VIMTALABS Stock Summary · May 2026
Robust FY'26 results showcased double‑digit growth but a cautious near‑term outlook, with FY'26 revenue at INR 4,163 million and EBITDA margins among the industry's best at roughly 35.8%. Management emphasized execution priorities: scaling recently expanded facilities to support four‑to‑five years of growth, building a biologics and peptide contract R&D capability (with readiness in processes and people but no expectation of meaningful revenue in the maiden year), and accelerating overseas business development including a U.S. subsidiary to deepen customer proximity. They struck an upbeat yet measured tone, highlighting strong pharmaceutical and seasonal food testing demand and exports contributing materially, while flagging tension from capacity ramp‑ups, maintenance and rising input and manpower costs that could pressure margins by 1–2% and cause near‑term volatility. Geopolitical and tariff headwinds were acknowledged as transient disruptors, and management described the balance sheet as net debt‑free with cash on hand and no current fundraising plans, refraining from firm forward guidance and framing near‑term prospects as conditional on geopolitical outcomes and gradual utilization gains.
VIMTALABS Stock Growth Drivers
VIMTALABS Stock Growth Drivers
8Strong financial performance with healthy margins and balance sheet
Vimta delivered double‑digit top‑line growth and margin strength in FY'26 and Q4, reflecting realized operational
Robust secular demand and favorable industry dynamics
The company is positioned to benefit from broad, durable tailwinds across its served markets as
VIMTALABS Stock Challenges
VIMTALABS Stock Challenges
5Geopolitical and trade disruptions creating near‑term revenue and operational headwinds
Geopolitical tensions and trade actions have already produced tangible negative effects and pose an ongoing
Margin compression from rising input and manpower costs with limited near‑term relief
The company expects an adverse impact to profitability driven by higher input costs and continuously
VIMTALABS Forecast
VIMTALABS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
VIMTALABS
VIMTALABS
Income
Balance Sheet
Cash Flow
Quarterly Normal View
VIMTALABS Income Statement
VIMTALABS Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 73.70 | 73.12 | 75.57 | 85.43 | 95.13 | 96.08 | 99.31 | 104.51 | 100.46 | 112.00 | ||||||||||
Operating & Other expenses | 52.18 | 48.43 | 50.57 | 56.61 | 56.84 | 61.40 | 63.88 | 67.62 | 66.02 | 69.88 | ||||||||||
EBITDA | 21.52 | 24.69 | 25.00 | 28.82 | 38.29 | 34.68 | 35.43 | 36.89 | 34.44 | 42.12 | ||||||||||
| Depreciation/Amortization | 8.38 | 7.84 | 7.98 | 8.29 | 9.81 | 9.21 | 9.86 | 10.24 | 10.92 | 12.75 | ||||||||||
| PBIT | 13.14 | 16.85 | 17.02 | 20.53 | 28.48 | 25.47 | 25.57 | 26.65 | 23.52 | 29.37 | ||||||||||
| Interest & Other Items | 0.53 | 0.53 | 0.47 | 0.41 | 0.58 | 0.44 | 0.32 | 0.37 | 0.16 | 0.32 | ||||||||||
| PBT | 12.61 | 16.32 | 16.55 | 20.12 | 27.90 | 25.03 | 25.25 | 26.28 | 23.36 | 29.05 | ||||||||||
| Taxes & Other Items | 3.16 | 3.97 | 4.26 | 4.88 | 6.40 | 6.71 | 6.36 | 6.35 | 5.78 | 7.93 | ||||||||||
| Net Income | 9.45 | 12.35 | 12.29 | 15.24 | 21.50 | 18.32 | 18.89 | 19.93 | 17.58 | 21.12 | ||||||||||
| EPS | 2.13 | 2.79 | 2.26 | 3.29 | 4.83 | 4.11 | 4.25 | 4.46 | 3.96 | 4.73 |
VIMTALABS Company Updates
VIMTALABS Stock Peers
VIMTALABS Past Performance & Peer Comparison
VIMTALABS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Vimta Labs Ltd | 31.47 | 5.34 | 0.37% |
| Divi's Laboratories Ltd | 68.32 | 11.72 | 0.45% |
| Syngene International Ltd | 57.63 | 3.86 | 0.28% |
| Aarti Pharmalabs Ltd | 33.25 | 2.92 | 0.55% |
VIMTALABS Stock Price Comparison
Compare VIMTALABS with any stock or ETFCompare VIMTALABS with any stock or ETF
VIMTALABS
VIMTALABS Holdings
VIMTALABS Shareholdings
VIMTALABS Promoter Holdings Trend
VIMTALABS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
VIMTALABS Institutional Holdings Trend
VIMTALABS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VIMTALABS Shareholding Pattern
VIMTALABS Shareholding Pattern
VIMTALABS Shareholding History
VIMTALABS Shareholding History
Foreign Institutions
Mutual Funds Invested in VIMTALABS
Mutual Funds Invested in VIMTALABS
No mutual funds holding trends are available
Top 1 Mutual Funds holding Vimta Labs Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.05% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 102/130 (-9) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing VIMTALABS stock
smallcases containing VIMTALABS stock
Looks like this stock is not in any smallcase yet.
VIMTALABS Events
VIMTALABS Events
VIMTALABS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VIMTALABS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.36%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.60 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VIMTALABS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VIMTALABS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.36%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.60 every year
VIMTALABS Upcoming Dividends
VIMTALABS Upcoming Dividends
Cash Dividend
Ex DateEx DateJun 18, 2026
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 18, 2026
VIMTALABS Past Dividends
VIMTALABS Past Dividends
Cash Dividend
Ex DateEx DateMay 30, 2025
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
May 30, 2025
Cash Dividend
Ex DateEx DateJul 11, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 11, 2024
Cash Dividend
Ex DateEx DateJun 21, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 21, 2023
Cash Dividend
Ex DateEx DateJun 16, 2022
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 16, 2022
Cash Dividend
Ex DateEx DateJun 25, 2021
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 25, 2021
VIMTALABS Stock News & Opinions
VIMTALABS Stock News & Opinions
Articles & Videos
Corporate
Corporate
Vimta Labs to conduct AGMVimta Labs announced that the Annual General Meeting(AGM) of the company will be held on 25 June 2026.
1 week agoCapital Market - Live
Earnings
Earnings
Vimta Labs standalone net profit rises 15.23% in the March 2026 quarterNet profit of Vimta Labs rose 15.23% to Rs 21.11 crore in the quarter ended March 2026 as against Rs 18.32 crore during the previous quarter ended March 2025. Sales rose 15.68% to Rs 109.25 crore in the quarter ended March 2026 as against Rs 94.44 crore during the previous quarter ended March 2025. For the full year,net profit rose 15.10% to Rs 77.51 crore in the year ended March 2026 as against Rs 67.34 crore during the previous year ended March 2025. Sales rose 18.41% to Rs 407.29 crore in the year ended March 2026 as against Rs 343.98 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales109.2594.44 16 407.29343.98 18 OPM %36.0334.99 -34.7535.45 - PBDT41.7934.24 22 149.34124.29 20 PBT29.0425.03 16 105.5789.00 19 NP21.1118.32 15 77.5167.34 15 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Board of Vimta Labs recommends final dividendVimta Labs announced that the Board of Directors of the Company at its meeting held on 6 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 100%) , subject to the approval of the shareholders.
1 month agoCapital Market - Live
Corporate
Corporate
Vimta Labs schedules board meetingVimta Labs will hold a meeting of the Board of Directors of the Company on 6 May 2026.
1 month agoCapital Market - Live
Earnings
Earnings
Vimta Labs standalone net profit declines 18.19% in the December 2025 quarterNet profit of Vimta Labs declined 18.19% to Rs 17.59 crore in the quarter ended December 2025 as against Rs 21.50 crore during the previous quarter ended December 2024. Sales rose 9.69% to Rs 98.63 crore in the quarter ended December 2025 as against Rs 89.92 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales98.6389.92 10 OPM %34.7236.79 - PBDT35.9133.73 6 PBT24.9923.92 4 NP17.5921.50 -18 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Vimta Labs schedules board meetingVimta Labs will hold a meeting of the Board of Directors of the Company on 28 January 2026.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Vimta Labs allots 94,369 equity shares under ESOPVimta Labs has allotted 94,369 equity shares under ESOP on 17 November 2025. With this allotment, the paid up equity share capital has increased to Rs 8,92,70,378 consisting of 4,46,35,189 equity shares having a face value of Rs 2 each. Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Earnings
Vimta Labs standalone net profit rises 30.62% in the September 2025 quarterNet profit of Vimta Labs rose 30.62% to Rs 19.92 crore in the quarter ended September 2025 as against Rs 15.25 crore during the previous quarter ended September 2024. Sales rose 20.19% to Rs 101.85 crore in the quarter ended September 2025 as against Rs 84.74 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales101.8584.74 20 OPM %33.6035.31 - PBDT36.5130.19 21 PBT26.2721.90 20 NP19.9215.25 31 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Vimta Labs to declare Quarterly ResultsVimta Labs will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Vimta Labs standalone net profit rises 53.83% in the June 2025 quarterNet profit of Vimta Labs rose 53.83% to Rs 18.89 crore in the quarter ended June 2025 as against Rs 12.28 crore during the previous quarter ended June 2024. Sales rose 30.29% to Rs 97.56 crore in the quarter ended June 2025 as against Rs 74.88 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales97.5674.88 30 OPM %34.5234.62 - PBDT35.1126.14 34 PBT25.2518.16 39 NP18.8912.28 54 Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.68%, vs industry avg of 10.53%
Over the last 5 years, market share increased from 1.82% to 1.83%
Over the last 5 years, net income has grown at a yearly rate of 57.62%, vs industry avg of 7.25%